Recently, a new type of small-molecule tyrosine kinase inhibitor involved in the VEGF, PDGF, FGFR, and c-Kit pathways, anlotinib, was approved for the treatment of NSCLC. This evidence concerns the gene KIT and non-small cell lung carcinoma.